GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Tactile Systems Technology Inc (NAS:TCMD) » Definitions » ROE %

Tactile Systems Technology (Tactile Systems Technology) ROE % : 17.43% (As of Dec. 2023)


View and export this data going back to 2016. Start your Free Trial

What is Tactile Systems Technology ROE %?

ROE % is calculated as Net Income divided by its average Total Stockholders Equity over a certain period of time. Tactile Systems Technology's annualized net income for the quarter that ended in Dec. 2023 was $32.8 Mil. Tactile Systems Technology's average Total Stockholders Equity over the quarter that ended in Dec. 2023 was $188.2 Mil. Therefore, Tactile Systems Technology's annualized ROE % for the quarter that ended in Dec. 2023 was 17.43%.

The historical rank and industry rank for Tactile Systems Technology's ROE % or its related term are showing as below:

TCMD' s ROE % Range Over the Past 10 Years
Min: -14.31   Med: 7.4   Max: 18.1
Current: 17.54

During the past 11 years, Tactile Systems Technology's highest ROE % was 18.10%. The lowest was -14.31%. And the median was 7.40%.

TCMD's ROE % is ranked better than
90.01% of 811 companies
in the Medical Devices & Instruments industry
Industry Median: 0.13 vs TCMD: 17.54

Tactile Systems Technology ROE % Historical Data

The historical data trend for Tactile Systems Technology's ROE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Tactile Systems Technology ROE % Chart

Tactile Systems Technology Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
ROE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 10.87 -0.52 -9.34 -14.31 18.10

Tactile Systems Technology Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
ROE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 15.68 -5.44 -0.25 52.22 17.43

Competitive Comparison of Tactile Systems Technology's ROE %

For the Medical Devices subindustry, Tactile Systems Technology's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Tactile Systems Technology's ROE % Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Tactile Systems Technology's ROE % distribution charts can be found below:

* The bar in red indicates where Tactile Systems Technology's ROE % falls into.



Tactile Systems Technology ROE % Calculation

Tactile Systems Technology's annualized ROE % for the fiscal year that ended in Dec. 2023 is calculated as

ROE %=Net Income (A: Dec. 2023 )/( (Total Stockholders Equity (A: Dec. 2022 )+Total Stockholders Equity (A: Dec. 2023 ))/ count )
=28.515/( (121.4+193.642)/ 2 )
=28.515/157.521
=18.10 %

Tactile Systems Technology's annualized ROE % for the quarter that ended in Dec. 2023 is calculated as

ROE %=Net Income (Q: Dec. 2023 )/( (Total Stockholders Equity (Q: Sep. 2023 )+Total Stockholders Equity (Q: Dec. 2023 ))/ count )
=32.808/( (182.83+193.642)/ 2 )
=32.808/188.236
=17.43 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is four times the quarterly (Dec. 2023) net income data. ROE % is displayed in the 30-year financial page.


Tactile Systems Technology  (NAS:TCMD) ROE % Explanation

ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.

The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:

ROE %(Q: Dec. 2023 )
=Net Income/Total Stockholders Equity
=32.808/188.236
=(Net Income / Revenue )*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(32.808 / 310.608)*(310.608 / 287.3725)*(287.3725 / 188.236)
=Net Margin %*Asset Turnover*Equity Multiplier
=10.56 %*1.0809*1.5267
=ROA %*Equity Multiplier
=11.41 %*1.5267
=17.43 %

With this breakdown, it is clear that if a company grows its Net Profit Margin, its Asset Turnover, or its Leverage, it can grow its ROE %.

The factors that affect a company's ROE % can also be illustrated with the five-step DuPont Analysis:

ROE %(Q: Dec. 2023 )
=Net Income/Total Stockholders Equity
=32.808/188.236
=(Net Income / Pre-Tax Income) * (Pre-Tax Income / Operating Income) * (Operating Income / Revenue) * (Revenue / Total Assets) * (Total Assets / Total Stockholders Equity)
= (32.808 / 47.056) * (47.056 / 49.428) * (49.428 / 310.608) * (310.608 / 287.3725) * (287.3725 / 188.236)
= Tax Burden * Interest Burden * Operating Margin % * Asset Turnover * Equity Multiplier
= 0.6972 * 0.952 * 15.91 % * 1.0809 * 1.5267
=17.43 %

Note: The net income data used here is four times the quarterly (Dec. 2023) net income data. The Revenue data used here is four times the quarterly (Dec. 2023) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Net Income is used.

Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.


Tactile Systems Technology ROE % Related Terms

Thank you for viewing the detailed overview of Tactile Systems Technology's ROE % provided by GuruFocus.com. Please click on the following links to see related term pages.


Tactile Systems Technology (Tactile Systems Technology) Business Description

Traded in Other Exchanges
Address
3701 Wayzata Boulevard, Suite 300, Minneapolis, MN, USA, 55416
Tactile Systems Technology Inc is a medical technology company. The company is engaged in developing and providing medical devices for the treatment of chronic diseases. The firm's proprietary platform flexitouch system provides a home-based solution for lymphedema patients. The entire system is another home solution for patients with chronic swelling and actitouch system for chronic venous insufficiency patients that may be worn throughout the day.
Executives
Boyd Vindell Washington director 1331 TYLER STREET NE, STE 200, MINNEAPOLIS MN 55413
Daniel L. Reuvers director, officer: President and CEO INTEGRA LIFESCIENCES CORPORATION, 311 ENTERPRISE DRIVE, PLAINSBORO NJ 08536
Sherri Lee Ferstler officer: Senior VP, Sales 1331 TYLER STREET NE, STE 200, MINNEAPOLIS MN 55413
William W Burke director 3868 MOCKINGBIRD LN, DALLAS TX 75205
Kristie Burns officer: Sr. VP Mktg & Clinical Affairs 3701 WAYZATA BLVD, MINNEAPOLIS MN 55416
Eric Pauls officer: Senior VP, Sales 3701 WAYZATA BLVD, SUITE 300, MINNEAPOLIS MN 55416
Elaine M. Birkemeyer officer: Chief Financial Officer 3701 WAYZATA BLVD, SUITE 300, MINNEAPOLIS MN 55416
Brent Moen officer: Chief Financial Officer 3600 HOLLY LANE NORTH, SUITE 40, PLYMOUTH MN 55447
Carmen B Volkart director C/O MODULAR MEDICAL, INC., 16772 WEST BERNARDO DRIVE, SAN DIEGO CA 92127
Valerie L. Asbury director 3701 WAYZATA BLVD, SUITE 300, MINNEAPOLIS MN 55416
David Brent Shafer director 2800 ROCKCREEK PARKWAY, NORTH KANSAS CITY MO 64117
Bryan Rishe officer: Vice President, Sales 1331 TYLER STREET NE, SUITE 200, MINNEAPOLIS MN 55413
Deepti Jain director 3701 WAYZATA BLVD, MINNEAPOLIS MN 55416
Sheri Louise Dodd director 3701 WAYZATA BLVD, SUITE 300, MINNEAPOLIS MN 55416
Gerald R. Mattys director, officer: Chief Executive Officer 1331 TYLER STREET NE, SUITE 200, MINNEAPOLIS MN 55413